Expression of IL-1α and IL-6 is Associated with Progression and Prognosis of Human Cervical Cancer

Abstract

BackgroundIL-1α and IL-6 are associated with the prognosis of a wide range of cancers, but their value in cervical cancer remains controversial. The aim of this study was to investigate the expression of IL-1α and IL-6 in cervical cancer and their significance in clinical prognosis.Material/MethodsThe expression of IL-1α and IL-6 in 105 formalin-fixed, paraffin-embedded cervical cancer tissues and adjacent non-tumor tissues was examined by immunohistochemistry. The results were semi-quantitatively scored and analyzed by chi-square test. Patient overall survival (OS) data was collected by follow-up and analyzed by Kaplan-Meier analysis.ResultsThe expression level of both IL-1α and IL-6 in cervical cancer tissue was higher than in adjacent non-tumor tissues (p<0.05). IL-1α expression was shown to be correlated with tumor size, FIGO histology grade, lymph node metastasis, stromal invasion, and tumor differentiation (p<0.05). IL-6 expression was shown to be correlated with tumor size, FIGO histology grade, and tumor differentiation (p<0.05). Patients with positive expression of IL-1α or IL-6 tended to have much shorter survival times than patients with negative expression. In addition, a multivariate Cox regression analysis demonstrated that IL-1α expression and lymph node metastasis were independent predictors of OS in cervical cancer patients.ConclusionsThe expression of IL-1α was significantly associated with tumor size, FIGO histology grade, lymph node metastasis, stromal invasion, and tumor differentiation. The expression of IL-6 was significantly associated with tumor size, FIGO histology grade, and tumor differentiation. Positive IL-1α and IL-6 expression was significantly correlated with poor prognosis. They may be considered valuable biomarkers for prognosis and potential therapeutic targets for cervical cancer.

Interleukin 1 gene polymorphism and susceptibility to disease

“…Association between high plasma levels of IL‐1β and IL‐1B genotypes was observed in women with cervical cancer, and may be considered a candidate biomarker for the disease . The local expression of IL‐1α in the cancer tissue is positively correlated with cancer size, grade, and lymph node metastasis . Genotype of IL‐1 system proteins, plasma concentrations of IL‐β, and tissue expression of IL‐1α can be considered as valuable biomarkers for prognosis, and potential therapeutic targets.…”

“…163,164 The local expression of IL-1α in the cancer tissue is positively correlated with cancer size, grade, and lymph node metastasis. 165 Genotype of IL-1 system proteins, plasma concentrations of ILβ, and tissue expression of IL-1α can be considered as valuable biomarkers for prognosis, and potential therapeutic targets.…”

Polymorphisms in IL‐1A are associated with endometrial cancer susceptibility among Chinese Han population: A case–control study

“…Sapkota et al studied the relationship between IL‐1A gene locus and endometriosis and found that IL‐1A rs3783550 increased the risk of endometriosis in Europeans but was not statistically significant (Sapkota et al, ). Song et al found that IL‐1a was highly expressed in cervical cancer tissue and also found that the prognosis of patients with IL‐1a positive expression was worse than IL‐1a negative expression (Song et al, ). Another study has also shown that the level of IL‐1a was higher in peritoneal fluid and serum of endometriosis patients than in participants without the disease (Kondera‐Anasz, Sikora, Mielczarek‐Palacz, & Jońca, ).…”

Cyr61 Expression Pattern and Association with Clinicopathological Factors in Patients with Cervical Cancer

“…Focusing on Cyr61-associated interactors, certain studies account for a signaling network in CC progression that clearly features the functional importance of Cyr61 activity. Song et al point out interleukins IL-1 and IL-6 as verisimilar valuable biomarkers and even potential therapeutic targets for CC (20). Most interestingly, Cyr61 is a known inducer of both factors, IL-1 (21) and IL-6 (22).…”